

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)

Name of Patentee Regeneron Pharmaceuticals, Inc.	Docket Number (Optional) P35058US10/1106854.00051
Patent Number 10,406,226	Date Patent Issued September 10, 2019

Title of Invention
METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS

I hereby disclaim the following complete claims in the above identified patent: 1-4


The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): Assignee of record (reel/frame: 043812/0974)

The fee for this disclaimer is set forth in 37 CFR 1.20(d).

- Patentee claims small entity status. See 37 CFR 1.27.
- Small entity status has already been established in this case, and is still proper.
- A check in the amount of the fee is enclosed.
- Payment by credit card. Form PTO-2038 is attached.
- The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 50-2387.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signed at TARRYTOWN, State of NEW YORK, this 03RD day of AUGUST, 2023.

	50,437
Signature	Registration Number, if applicable
Frank Cottingham VP, Associate General Counsel, Intellectual Property, Regeneron Pharmaceuticals, Inc.	914-847-1116
Typed or printed name of patentee/ attorney or agent of record	Telephone Number

777 Old Saw Mill River Road

Address

Tarrytown, NY 10591-6707

City, State, Zip Code or Foreign Country as applicable

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Celltrion v. Regeneron
IPR2023-00620
U.S. Pat. 10,406,226, Exhibit 2001



ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #
15/692,893

RECEIPT DATE / TIME
08/04/2023 09:22:18 AM ET

ATTORNEY DOCKET #
P35058US10/1106854.00051

Title of Invention

METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 10406226

CONFIRMATION # 8858

FILED BY Kathi Moore

PATENT CENTER # 62558560

FILING DATE 08/31/2017

CUSTOMER # 191459

FIRST NAMED INVENTOR Daniel B. DIX

CORRESPONDENCE ADDRESS -

AUTHORIZED BY Michael Lewis

Documents

TOTAL DOCUMENTS: 1

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
P35058US10-Executed-by-Assignee.pdf	1	Statutory disclaimers per Manual of Patent Examining Procedure(MPEP) 1490.	387 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
P35058US10-Executed-by-Assignee.pdf	4FC3347C6B8B977D4F884737ED8E178F05B68CD55A1DC8764680223B6C0B772E9FBFE5058A1F5838E42C9359D4447D58E2EA301E812F1612A2E330C87269615B

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



ELECTRONIC PAYMENT RECEIPT

APPLICATION #
15/692,893

RECEIPT DATE / TIME
08/04/2023 09:22:18 AM ET

ATTORNEY DOCKET #
P35058US10/1106854.00051

Title of Invention

METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 10406226

CONFIRMATION # 8858

FILED BY Kathi Moore

PATENT CENTER # 62558560

AUTHORIZED BY Michael Lewis

CUSTOMER # 191459

FILING DATE 08/31/2017

CORRESPONDENCE ADDRESS -

FIRST NAMED INVENTOR Daniel B. DIX

Payment Information

PAYMENT METHOD
CARD / 0128

PAYMENT TRANSACTION ID
E202384023318703

PAYMENT AUTHORIZED BY
Michael Lewis

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
1814	STATUTORY DISCLAIMER, INCLUDING TERMINAL DISCLAIMER	170.00	1	170.00
			TOTAL AMOUNT:	\$170.00

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

Regeneron Exhibit 2001
Page 04 of 05

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.